IceCure Medical (NASDAQ:ICCM) Shares Up 1% – What’s Next?

IceCure Medical Ltd. (NASDAQ:ICCM)’s share price shot up 1% during trading on Monday . The company traded as high as $0.6646 and last traded at $0.6505. 141,646 shares traded hands during trading, a decline of 53% from the average session volume of 300,959 shares. The stock had previously closed at $0.6440.

Analysts Set New Price Targets

ICCM has been the topic of several research reports. HC Wainwright increased their price target on shares of IceCure Medical from $2.00 to $2.50 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.64.

IceCure Medical Stock Up 1.0%

The stock has a 50-day moving average price of $0.67 and a 200 day moving average price of $0.84. The firm has a market capitalization of $44.69 million, a price-to-earnings ratio of -2.50 and a beta of 0.29.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, November 19th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). IceCure Medical had a negative net margin of 513.95% and a negative return on equity of 243.68%. The firm had revenue of $0.85 million during the quarter, compared to analysts’ expectations of $0.63 million. As a group, equities analysts forecast that IceCure Medical Ltd. will post -0.28 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.